Leading Clinical Development of Novel Compounds for Anemia and Fibrosis
Life Science Partner announced today the recruitment of Russell Ellison, MD, to become Vice President, Clinical and Medical Affairs at FibroGen, a biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis and Hypoxia-Inducible Factor (HIF) biology to discover, develop and commercialize novel therapeutics for fibrotic disorders, anemia, ischemic disease, cancer and other areas of unmet medical needs. FibroGen also develops and produces recombinant human collagens and gelatins using unique production technology that provides the basis for FibroGen’s proprietary cosmetic dermal filler and biomaterials supply business.
“Russ was attracted to FibroGen due to its extensive portfolio of compounds marching steadily toward the clinic and their potential to dramatically improve the lives of patients with anemia and other life-threatening diseases,” said Thomas H. Callaway, MD, Founder and President of Life Science Partner. “His combination of FDA regulatory experience and global medical affairs made him a perfect fit for this emerging pharmaceutical company,” he added.
Prior to his recruitment to FibroGen, Ellison was Vice President, Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo USA, with responsibility for building its best-in-class medical affairs, regulatory and safety teams. He oversaw the clinical development of key products such as Plavix and Ambien, and was renown for reducing project development timelines and improving relations with managed care companies.
Ellison was recruited to Sanofi from Hoffmann La Roche. As Vice President, Medical Affairs and the Chief Medical Officer, he oversaw a 300-member organization that oversaw clinical trials, managed medical strategy, intervened on behalf of the company with regulatory agencies and developed clinical development strategies in sync with the company’s commercial strategies for its compounds in development. He was noted by his peers as a rare physician who understood the business aspects, as well as the clinical implications of the pharmaceutical industry.
A Canadian physician, Ellison has a global understanding of drug development and registration, as well as the challenges of reimbursement and clinical acceptance of new drugs. At FibroGen, his skills will be valuable as he builds the clinical and regulatory teams and moves the products from the pre-clinical to clinical development phase.